We are a profitable and growing company focused on the acquisition, development and commercialization of branded prescription products for specialty physician market segments. Since our inception in 1999, we have successfully funded the acquisition and development of our product portfolio with limited external investment, and have been profitable since 2004. We believe we have significant growth opportunities with our existing product portfolio and we continue to identify and pursue other promising product candidates. Source
No articles found.
Aravive is developing treatments designed to halt progression of life-threatening ...
Aravive is developing treatments designed to ha...
Fibrocell is a cell and gene therapy company focused on improving the lives of peo...
Fibrocell is a cell and gene therapy company fo...
Arena Pharmaceuticals is driven to deliver novel, transformational medicines with ...
Arena Pharmaceuticals is driven to deliver nove...
Founded on September 28, 2005 through the merger of Daiichi Pharmaceutical and San...
Founded on September 28, 2005 through the merge...
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage specialty pharmaceutical company i...
PLx Pharma Inc. (Nasdaq: PLXP), is a late-stage...
Checkpoint Therapeutics, Inc. (âCheckpointâ) is a clinical-stage, immuno-oncol...
Checkpoint Therapeutics, Inc. (âCheckpointâ...
The Company is a blank check company formed for the purpose of effecting a share e...
The Company is a blank check company formed for...
Join the National Investor Network and get the latest information with your interests in mind.